NCT05682638View on ClinicalTrials.gov

A Global Multi-center Clinical Study of SARS-CoV-2 mRNA Vaccine for the Prevention of COVID-19

PHASE3RecruitingINTERVENTIONAL
Enrollment

34,000

Participants

Timeline

Start Date

January 30, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions
SARS-CoV-2
Interventions
BIOLOGICAL

LVRNA009

100μg/1.0ml/dose(50 μg/0.5ml/Vial), 2 injection with 28 days apart

OTHER

0.9%NaCl

1.0ml/dose, 2 injection with 28 days apart

Trial Locations (1)

144-40600

RECRUITING

KEMRI CRDR Research Annex, Siaya Country Referral Hospital, Siaya

Sponsors

Collaborators (1)

LiveRNA Therapeutics Inc.
All Listed Sponsors
collaborator

AIM Innovation Biotechnology (Shanghai) Co., Ltd

UNKNOWN

collaborator

Ningbo Rongan Biological Pharmaceutical Co., Ltd.

INDUSTRY

collaborator

LiveRNA Therapeutics Inc.

UNKNOWN

lead

AIM Vaccine Co., Ltd.

INDUSTRY